CD274 and neoplasm: However, the relatively low success rate of anti-PD-L1/PD-1 treatments in TNBC suggests that mechanisms that are not related to immune suppression were not affected by such ICBs and that other tumor-promoting events remain active at the course of immunotherapy and support tumor progression.